Comprehensive Molecular Characterization Identifies Distinct Genomic and Immune Hallmarks of Renal Medullary CarcinomaPavlos Msaouel, Nizar M. Tannir, Jianjun Gao et al.|Cancer Cell|2020Cited by 142
Combination antiangiogenic tyrosine kinase inhibition and anti‐PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomesAndrew Leonard Laccetti, Matthew T. Campbell, Benjamin Garmezy et al.|Cancer Medicine|2021Cited by 19
Nivolumab plus ipilimumab induce hyper-progression in renal medullary carcinoma: results of a phase II trial and preclinical evidenceMelinda Soeung, Pavlos Msaouel|Nature Communications|2025Cited by 4